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848-6 Aortic Valve Calcification and C-Reactive Protein 
Contribute Independently to Coronary Heart Disease 
Incidence
Bobak Salami, Dave Shavelle, Min Xiang, Laurie LaBree, Stanley Azen, Miwa Kawakubo, 
Agnes Papa, Kevin O'Brien, Robert Detrano, Harbor-UCLA Research & Education 
Institue, Torrance, CA, University of Southern California, Los Angeles, CA
Background:
Recent studies suggest that inflammation and aortic valve calcium (AVC) play a role in
the pathogenesis of subsequent cardiovascular events. We sought to determine whether
C-reactive protein (CRP) and AVC are associated with events.
Methods:
858 non-diabetic participants in the South Bay Heart Watch without underlying coronary
heart disease underwent baseline risk factor screening (including CRP levels) and non
contrast gated computed tomography for AVC. Abnormal AVC was defined as > 75th per-
centile of the non zero values (>140 score units) and was present in 41 participants
(4.8%). Mean follow-up was 7.0 +/- 0.5 years. AVC was measured using the method of
the MESA study. Abnormal CRP was defined as > 75th percentile (>3.97 mg/L). Out-
comes of non-fatal myocardial infarction, coronary death, coronary revascularization, or
stroke were considered. Cox regression analysis was performed to determine the effect
of AVC and CRP on clinical outcomes.
Results:
Results are shown in the table. Participants with both elevated AVC and CRP were more
likely to suffer subsequent events than participants with only one of these findings
(P=0.0004).
Conclusion:
A high AVC score in combination with elevated CRP in an asymptomatic person portends
a higher risk for future cardiovascular events than either high AVC or CRP alone.
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1159-183 Circulating T Cell Perturbation and Macrophage 
Activation in Stable Coronary Artery Disease Patients: 
Effect of Atorvastatin Therapy
Hannes F. Alber, Jakob Dörler, Matthias Frick, Wolfgang Dichtl, Ralf-Harun Zwick, Otmar 
Pachinger, Franz Weidinger, University Clinic of Innsbruck, Innsbruck, Austria
Background: 
Coronary artery disease (CAD) is characterized by both T lymphocyte and macrophage
activation. Statins have anti-inflammatory effects beyond lipid lowering. Whether these
also affect the global immune system is unclear. The aim of this study was to investigate
the influence of atorvastatin (atv) on circulating inflammatory T helper lymphocytes
(TH1), on their circulating activation marker soluble CD40 ligand (sCD40L), on the solu-
ble intercellular adhesion molecule-1 (sICAM-1), involved in lymphocyte recruitment and
on neopterin, a macrophage activation marker.
Methods: 
30 hypercholesterolemic patients with angiographically documented stable CAD were
randomized in a double-blind study to placebo or atv (20mg/d) for 3 months. Eight healthy
volunteers served as controls. sCD40L, sICAM-1, neopterin and C-reactive protein
(CRP) levels were measured with ELISA. TH1 and anti-inflammatory T helper (TH2) lym-
phocytes were characterized by intracellular staining of interleukin-2, specific for TH1,
and interleukin-4, specific for TH2 cells, by FACS analysis.
Results: 
TH1 cells (47.9±10.8 vs 31.5±10.5%, p<0.002), neopterin (7.0±2.5 vs 4.5±1.3nmol/L,
p<0.002), sCD40L (10.4± 4.5 vs 6.6±1.6ng/mL, p<0.01), sICAM-1 (251.8±83.6 vs 127.9±
58.7mg/dL, p<0.001) and CRP levels (0.47±0.40 vs 0.07±0.05mg/dL, p<0.001) were
increased in CAD patients compared to controls. TH2 cells were not different. LDL cho-
lesterol was reduced by 37.3±16.5% in atv-treated patients (p<0.001) and by 8.2±15.7%
(p=0.041) in the placebo group. TH1 and TH2 lymphocytes did not change in both groups.
By contrast, neopterin (p<0.02), sCD40L (p<0.02), sICAM-1 (p<0.01) and CRP (p<0.01)
were decreased in the atv group, but remained similar in the placebo group.
Conclusion: 
Our data suggest that a systemic immune activation is present also in stable CAD
patients. This activation is partially abolished by atorvastatin, supporting anti-inflamma-
tory properties of this agent.
1159-184 Maternal Undernutrition and Early Postnatal Diet Affect 
Aortic Structure and Composition in Rats
Michael R. Skilton, Lisa M. Ho, Alison K. Gosby, Ian D. Caterson, David S. Celermajer, 
University of Sydney, Sydney, Australia
Many epidemiologic studies suggest a link between fetal and early infant nutrition, and
predisposition to adult hypertension and coronary artery disease. We therefore examined
the effects of altering nutrition during gestation, lactation, and then throughout juvenile
life, on aortic structure and composition in rats.
Wistar rat dams were fed either a control (20% protein, 4% fat) or low protein (8% protein,
4% fat; LP) diet throughout pregnancy, or a low protein diet for the final 7 days of gesta-
tion only (LLP – last trimester low protein diet). At 21 days post-partum, 56 male pups
were weaned onto a control, LP or high fat diet (20% protein, 25% fat). All diets were iso-
caloric. At 12 weeks, rats were euthanased, the thoracic aorta perfusion fixed in situ and
then harvested. Aortic sections (6um thick) were stained with resorcin-fuchsin, to assess
elastin content. Media thickness, lumen diameter and elastin content were measured
using NIH Image software (blinded analysis).
Rats belonging to the maternal LP group had significantly reduced aortic lumen size
(1.80 ± 0.03 vs 2.03 ± 0.05mm) and media thickness (128 ± 4 vs 143 ± 4um), when com-
pared with controls (p<0.01). The maternal LLP group exhibited an increased percentage
of elastin in the aortic wall (66 ± 1 vs 62 ± 1%, p<0.05) when compared with controls,
while media thickness (137 ± 6um) and lumen diameter (2.10 ± 0.19mm) were unaf-
fected. Regarding the effect of post-natal diet, low protein was associated with a further
significant reduction in media thickness (p<0.05), but no change in lumen size or wall
composition. A high fat diet after birth did not affect aortic parameters.
In conclusion, protein restriction throughout gestation results in significant reductions in
aortic wall thickness and lumen size, exacerbated further by protein restriction after birth.
These changes may contribute to the observed association between undernutrition in
fetal/early life and vascular disease in adults.
1159-185 Smoking-Related Endothelial Dysfunction and 
Increased Serum Levels of Proinflammatory Cytokines 
and Adhesion Molecules Are Reversible by Antioxidant 
Treatment
Charalambos Antoniadis, Dimitrios Tousoulis, Marina Toutouza, Costas Tentolouris, 
Carmen Vasiliadou, Kyriakoula Marinou, Costas Tsioufis, Emmanuel Vavuranakis, 
Christos Pitsavos, Christodoulos Stefanadis, Athens Univeristy Medical School, Athens, 
Greece
Introduction: Smoking-related endothelial dysfunction and increased levels of interleuk-
ines 1b (IL-1b) and 6 (IL-6), tumor necrosis factor alpha (TNF-a), vascular cell adhesion
molecule (sVCAM-1), intercellular adhesion molecule (sICAM-1) and lipid hydroperox-
ides (LPO), are implicated in atherogenesis. The effect of combined administration of
vitamins C and E on endothelial function, lipid peroxidation and inflammatory process in
smokers is unknown.
Methods: Forty-two healthy smokers (aged 36±2 yrs old) received vitamin C 2g/d (n=10,
VITC), vitamin C 2g/d plus vitamin E 400IU/d (n=11, VITCE400), vitamin C 2g/d plus vita-
min E 800IU/day (n=10, VITCE800) or no treatment (n=11, Controls), for 4 weeks. Fore-
arm blood flow was measured using venous occlusion strain gauge plethysmography.
Endothelium dependent dilation (EDD) and endothelium independent dilation were
expressed as the %change of flow from rest to the maximum flow during reactive hypere-
mia or after sublingual nitroglycerine administration respectively. Inflammatory markers
were determined with ELISA and LPO spectrocolorimetrically.
Results: EDD was increased in VITCE400 (46.5±5.4 to 74.3±9.2%, p<0.01) and
VITCE800 (43.6±3.9 to 74.9±4.2%, p<0.001), but not in VITC and control groups. Simi-
larly, LPO was reduced in VITCE400 and VITCE800 groups (14.5±1.2 and 15.4±2.9 to
8.8±1.6 and 8.3±1.7 µM respectively, p<0.05 for both) only. However, in VITCE800, a sig-
nificant decrease was observed in levels of IL-1b (0.31±0.07 to 0.10±0.02 pg/ml, p<0.05),
IL-6 (4.69±0.90 to 2.02±0.71 pg/ml,p<0.05), sVCAM-1 (339±14 to 298±11 ng/ml, p<0.05)
and sICAM-1 (318±21 to 250±19 ng/ml, p<0.05), while TNF-a levels were slightly but not
significantly decreased (1.76±0.343 to 1.27±0.074 pg/ml, p=NS). All the above parame-
ters remained unchanged in VITC, VITCE400 and control groups.
Conclusions: Combined treatment with vitamins C (2g/day) and E (400 or 800IU/day),
decreased lipid peroxidation and improved endothelial function in smokers. Combined
administration of vitamins C (2g/d) and E (800IU/d) also decreased levels of IL-1b, IL-6,
sVCAM-1 and sICAM-1 in these subjects.
1159-186 High- but Not Low-Dose Folic Acid Improves 
Endothelial Function in Coronary Artery Disease
Anil K. Madhavan, Stuart J. Moat, Ian F. McDowell, Malcolm J. Lewis, Jonathan 
Goodfellow, Derek Lang, Wales Heart Research Institute, Cardiff, United Kingdom
Background: Previous studies have demonstrated that high dose folic acid can improve
endothelial function in coronary artery disease (CAD). However, the most efficacious
dose of folic acid and the significance of homocysteine-lowering remain unclear. There-
fore we sought to investigate the effects of both high dose (5mg/day) and low dose
(400µg/day) folic acid supplementation on homocysteine-lowering and endothelial func-
tion in CAD.
Methods: 75 CAD patients entered a randomised, double blind, placebo controlled study
comprising 3 parallel treatment groups (placebo, high and low dose folic acid). Endothe-
lial function, assessed by flow-mediated dilatation (FMD) of the brachial artery, was mea-
sured before and after 6 weeks treatment. Plasma folate, B12, total homocysteine, lipid
profile, glucose and creatinine were also measured before and after treatment. All data
are expressed as mean ± standard deviation.
Results: No significant changes in any parameters were observed in the placebo treated
group. Treatment with high dose and low dose folic acid significantly (p<0.001) increased
CRP-, AVC- CRP-, AVC+ CRP+,
AVC-
CRP+,
AVC+
RR 1.0 1.63 1.32 4.28
95% CI --- 0.70-3.79 0.86-2.02 1.92-9.57
P --- 0.26 0.21 0.0004
